Oxurion（TG40）株式概要バイオ医薬品会社オクスリオンNVは、ベルギーで失明予防薬を開発している。 詳細TG40 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( €355K )キャッシュランウェイが1年未満である マイナスの株主資本 +1 さらなるリスクすべてのリスクチェックを見るTG40 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.000253.8% 割高 内在価値ディスカウントEst. Revenue$PastFuture-60m23m2016201920222025202620282031Revenue €16.0kEarnings €2.9kAdvancedSet Fair ValueView all narrativesOxurion NV 競合他社bioXXmedSymbol: DB:T5OMarket cap: €222.9kEpigenomicsSymbol: DB:ECXMarket cap: €763.0kDarwinSymbol: MUN:7V0Market cap: €68.4mGenetic AnalysisSymbol: DB:8V8Market cap: €42.7m価格と性能株価の高値、安値、推移の概要Oxurion過去の株価現在の株価€0.000252週高値€0.04452週安値€0.0002ベータ-0.151ヶ月の変化0%3ヶ月変化0%1年変化-99.43%3年間の変化-99.90%5年間の変化-99.90%IPOからの変化-99.90%最新ニュースお知らせ • May 06Oxurion NV, Annual General Meeting, Jun 01, 2026Oxurion NV, Annual General Meeting, Jun 01, 2026, at 14:00 Romance Standard Time.お知らせ • Nov 10Oxurion NV to Report Fiscal Year 2025 Results on Apr 03, 2026Oxurion NV announced that they will report fiscal year 2025 results on Apr 03, 2026お知らせ • Jul 23Oxurion NV announced that it expects to receive €10 million in funding from Atlas Special Opportunities LLCOxurion NV entered into a term sheet agreement for a private placement to issue 6% convertible bonds for the proceeds of €10 million on July 22, 2025. The transaction involves participation of Atlas Special Opportunities LLC as returning investor. The bonds matures on 12 months from issuance and bears 6% interest. The expected closing of transaction is end of August 2025 and transaction will happen in 10 tranches.お知らせ • Apr 07Oxurion NV, Annual General Meeting, May 13, 2025Oxurion NV, Annual General Meeting, May 13, 2025.Reported Earnings • Oct 03First half 2024 earnings releasedFirst half 2024 results: Net loss: €3.03m (loss narrowed 72% from 1H 2023).Reported Earnings • Apr 17Full year 2023 earnings released: €0.01 loss per share (vs €0.37 loss in FY 2022)Full year 2023 results: €0.01 loss per share (improved from €0.37 loss in FY 2022). Net loss: €19.0m (loss narrowed 40% from FY 2022).最新情報をもっと見るRecent updatesお知らせ • May 06Oxurion NV, Annual General Meeting, Jun 01, 2026Oxurion NV, Annual General Meeting, Jun 01, 2026, at 14:00 Romance Standard Time.お知らせ • Nov 10Oxurion NV to Report Fiscal Year 2025 Results on Apr 03, 2026Oxurion NV announced that they will report fiscal year 2025 results on Apr 03, 2026お知らせ • Jul 23Oxurion NV announced that it expects to receive €10 million in funding from Atlas Special Opportunities LLCOxurion NV entered into a term sheet agreement for a private placement to issue 6% convertible bonds for the proceeds of €10 million on July 22, 2025. The transaction involves participation of Atlas Special Opportunities LLC as returning investor. The bonds matures on 12 months from issuance and bears 6% interest. The expected closing of transaction is end of August 2025 and transaction will happen in 10 tranches.お知らせ • Apr 07Oxurion NV, Annual General Meeting, May 13, 2025Oxurion NV, Annual General Meeting, May 13, 2025.Reported Earnings • Oct 03First half 2024 earnings releasedFirst half 2024 results: Net loss: €3.03m (loss narrowed 72% from 1H 2023).Reported Earnings • Apr 17Full year 2023 earnings released: €0.01 loss per share (vs €0.37 loss in FY 2022)Full year 2023 results: €0.01 loss per share (improved from €0.37 loss in FY 2022). Net loss: €19.0m (loss narrowed 40% from FY 2022).New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€8.6m). Earnings have declined by 1.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€515k revenue, or US$547k). Market cap is less than US$10m (€575.4k market cap, or US$611.5k). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).お知らせ • Apr 06Oxurion NV to Report Fiscal Year 2023 Results on Apr 15, 2024Oxurion NV announced that they will report fiscal year 2023 results on Apr 15, 2024お知らせ • Jan 25Oxurion NV, Annual General Meeting, May 07, 2024Oxurion NV, Annual General Meeting, May 07, 2024, at 14:00 Central European Standard Time.お知らせ • Dec 30+ 2 more updatesOxurion Announces CEO ChangesOxurion NV announced it has avoided bankruptcy by entering into a binding letter of intent (LOI) with Atlas Special Opportunities LLC (Atlas) and an addendum to the existing subscription agreement for convertible bonds with Atlas. The Company appointed Pascal Ghoson as the new acting CEO/CFO, who is a former M&A specialist at Rothschild bank and CFO of various listed companies on Euronext. Tom Graney have stepped down from the Board as a condition of the LOI.お知らせ • Nov 20Oxurion NV Discloses Topline Data from Kalahari Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular EdemaOxurion NV announced that topline data in its KALAHARI Phase 2, Part B clinical trial for Diabetic macular edema (DME) (KALAHARI trial) did not demonstrate that its novel PKal Inhibitor, THR-149, improved vision as much as the comparator, the anti-VEGF therapy aflibercept, at Month 3 (the primary endpoint). The mean change in best corrected visual acuity (BCVA) from baseline at Month 3 was -0.2 letters for theTHR-149 arm and +3.5 letters for the aflibercept arm. The results confirmed that THR-149 was safe and well tolerated. The KALAHARI trial is the only ongoing trial sponsored by Oxurion. In light of these results and the Company's low cash position, the Company has therefore decided to take the necessary steps to file for bankruptcy. Oxurion's investigators over-enrolled the trial with a total of 112 patients, for whom the current standard of care is suboptimal in treating their DME, reflecting the strong interest of both investigators and patients. The KALAHari trial evaluated Oxurion's novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for DME patients who respond suboptimally to anti-VEGF therapy. The continuation of the trial followed the recommendation from an Independent Data Monitoring Committee (IDMC) in December 2022 that it would not be futile for the KALAHARI trial to continue based on the outcome of a pre-specified futility analysis that included an evaluation of interim efficacy and safety data from 31 patients at Month 3 and followed encouraging data from the Part A dose- selection part of the KALAHARI trial.Board Change • Nov 06High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Independent Non-Executive Director Thomas Clay is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 05First half 2023 earnings released: €0.02 loss per share (vs €0.32 loss in 1H 2022)First half 2023 results: €0.02 loss per share (improved from €0.32 loss in 1H 2022). Net loss: €10.6m (loss narrowed 27% from 1H 2022).Board Change • Sep 20High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Independent Non-Executive Director Thomas Clay is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Aug 24Oxurion NV to Report First Half, 2023 Results on Sep 29, 2023Oxurion NV announced that they will report first half, 2023 results on Sep 29, 2023お知らせ • May 26Oxurion NV Reaches Enrollment Target in Kalahari Phase 2, Part B Trial of Novel Pkal Inhibitor Thr-149 in Diabetic Macular EdemaOxurion NV announced that it has reached its enrollment target of 108 patients randomized in its KALAHARI Phase 2, Part B clinical trial for diabetic macular edema (DME) (KALAHARI trial). As of Oxurion’s investigators have successfully enrolled the 108 patients planned for this trial. Given the high level of interest from both investigators and patients, additional patients are still likely to be included in the trial, which would mean the trial will be over-enrolled. As it has now reached its enrollment target, Oxurion confirms its previous guidance that it anticipates reporting top-line data from the KALAHARI trial in the fourth quarter of 2023. The KALAHARI trial is evaluating Oxurion’s novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for DME patients who respond suboptimally to anti-VEGF therapy, the current standard of care. This milestone follows the recommendation from an Independent Data Monitoring Committee (IDMC) in December 2022 that the KALAHARI trial should continue based on the outcome of a pre-specified futility analysis that included an evaluation of interim efficacy and safety data from 31 patients at the three-month time point. Approximately 22 million people worldwide have DME currently, with prevalence increasing due to the growing global diabetic epidemic. DME is the leading cause of vision loss in working-age people, and the market for treatments is currently estimated at +$5 billion. People who suffer from DME have leaking vessels in the back of the eye, leading to a thickening of the retina that causes vision problems such as blurriness in the center of vision, the appearance of dark spots or patches in the field of vision, and colors to look dull. These symptoms may affect the ability to read, write, drive, and recognize faces – presenting a significant patient and caregiver burden.Board Change • May 19High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Independent Non-Executive Director Thomas Clay is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 21Oxurion NV, Annual General Meeting, May 02, 2023Oxurion NV, Annual General Meeting, May 02, 2023.Reported Earnings • Feb 24Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: €0.77 loss per share (down from €0.73 loss in FY 2020). Net loss: €29.2m (loss widened 4.1% from FY 2020). Products in clinical trials Phase I: 1 Phase II: 1 Revenue exceeded analyst estimates by 147%. Over the next year, revenue is expected to shrink by 100% compared to a 59% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 20Full year 2020 earnings released: €0.75 loss per share (vs €1.35 loss in FY 2019)Full year 2020 results: Net loss: €28.0m (loss narrowed 46% from FY 2019). Products in clinical trials Phase I: 1 Phase II: 1 Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Nov 28New 90-day high: €2.92The company is up 19% from its price of €2.45 on 28 August 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 5.0% over the same period.Is New 90 Day High Low • Oct 30New 90-day low: €2.35The company is down 15% from its price of €2.78 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 14% over the same period.Is New 90 Day High Low • Oct 01New 90-day low: €2.40The company is down 20% from its price of €3.02 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.Reported Earnings • Sep 19First half earnings releasedOver the last 12 months the company has reported total losses of €31.6m, with losses narrowing by 44% from the prior year.株主還元TG40DE BiotechsDE 市場7D0%1.8%2.4%1Y-99.4%-12.5%1.2%株主還元を見る業界別リターン: TG40過去 1 年間で-12.5 % の収益を上げたGerman Biotechs業界を下回りました。リターン対市場: TG40は、過去 1 年間で1.2 % のリターンを上げたGerman市場を下回りました。価格変動Is TG40's price volatile compared to industry and market?TG40 volatilityTG40 Average Weekly Movement0%Biotechs Industry Average Movement8.5%Market Average Movement6.1%10% most volatile stocks in DE Market13.4%10% least volatile stocks in DE Market2.7%安定した株価: データは利用できません。時間の経過による変動: 過去 1 年間のTG40のボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト199111Pascal Ghosonwww.oxurion.comオクスリオンNV社は、ベルギーで失明予防薬の開発を行っているバイオ医薬品企業である。同社は、地理的萎縮や加齢黄斑変性などの網膜疾患患者の視力を維持するための眼科治療薬を開発している。同社は以前はThromboGenics NVとして知られていたが、2018年9月にOxurion NVに社名を変更した。Oxurion NVは1991年に設立され、ベルギーのルーヴェンに本社を置いている。もっと見るOxurion NV 基礎のまとめOxurion の収益と売上を時価総額と比較するとどうか。TG40 基礎統計学時価総額€354.77k収益（TTM）-€3.73m売上高(TTM)€555.00k0.6xP/Sレシオ-0.1xPER（株価収益率TG40 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計TG40 損益計算書（TTM）収益€555.00k売上原価€0売上総利益€555.00kその他の費用€4.28m収益-€3.73m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.042グロス・マージン100.00%純利益率-671.71%有利子負債／自己資本比率-89.0%TG40 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 15:28終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Oxurion NV 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Roderick VerhelstDegroof PetercamDivya HarikeshGoldman SachsSteven ChesneyGoldman Sachs7 その他のアナリストを表示
お知らせ • May 06Oxurion NV, Annual General Meeting, Jun 01, 2026Oxurion NV, Annual General Meeting, Jun 01, 2026, at 14:00 Romance Standard Time.
お知らせ • Nov 10Oxurion NV to Report Fiscal Year 2025 Results on Apr 03, 2026Oxurion NV announced that they will report fiscal year 2025 results on Apr 03, 2026
お知らせ • Jul 23Oxurion NV announced that it expects to receive €10 million in funding from Atlas Special Opportunities LLCOxurion NV entered into a term sheet agreement for a private placement to issue 6% convertible bonds for the proceeds of €10 million on July 22, 2025. The transaction involves participation of Atlas Special Opportunities LLC as returning investor. The bonds matures on 12 months from issuance and bears 6% interest. The expected closing of transaction is end of August 2025 and transaction will happen in 10 tranches.
お知らせ • Apr 07Oxurion NV, Annual General Meeting, May 13, 2025Oxurion NV, Annual General Meeting, May 13, 2025.
Reported Earnings • Oct 03First half 2024 earnings releasedFirst half 2024 results: Net loss: €3.03m (loss narrowed 72% from 1H 2023).
Reported Earnings • Apr 17Full year 2023 earnings released: €0.01 loss per share (vs €0.37 loss in FY 2022)Full year 2023 results: €0.01 loss per share (improved from €0.37 loss in FY 2022). Net loss: €19.0m (loss narrowed 40% from FY 2022).
お知らせ • May 06Oxurion NV, Annual General Meeting, Jun 01, 2026Oxurion NV, Annual General Meeting, Jun 01, 2026, at 14:00 Romance Standard Time.
お知らせ • Nov 10Oxurion NV to Report Fiscal Year 2025 Results on Apr 03, 2026Oxurion NV announced that they will report fiscal year 2025 results on Apr 03, 2026
お知らせ • Jul 23Oxurion NV announced that it expects to receive €10 million in funding from Atlas Special Opportunities LLCOxurion NV entered into a term sheet agreement for a private placement to issue 6% convertible bonds for the proceeds of €10 million on July 22, 2025. The transaction involves participation of Atlas Special Opportunities LLC as returning investor. The bonds matures on 12 months from issuance and bears 6% interest. The expected closing of transaction is end of August 2025 and transaction will happen in 10 tranches.
お知らせ • Apr 07Oxurion NV, Annual General Meeting, May 13, 2025Oxurion NV, Annual General Meeting, May 13, 2025.
Reported Earnings • Oct 03First half 2024 earnings releasedFirst half 2024 results: Net loss: €3.03m (loss narrowed 72% from 1H 2023).
Reported Earnings • Apr 17Full year 2023 earnings released: €0.01 loss per share (vs €0.37 loss in FY 2022)Full year 2023 results: €0.01 loss per share (improved from €0.37 loss in FY 2022). Net loss: €19.0m (loss narrowed 40% from FY 2022).
New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€8.6m). Earnings have declined by 1.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€515k revenue, or US$547k). Market cap is less than US$10m (€575.4k market cap, or US$611.5k). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).
お知らせ • Apr 06Oxurion NV to Report Fiscal Year 2023 Results on Apr 15, 2024Oxurion NV announced that they will report fiscal year 2023 results on Apr 15, 2024
お知らせ • Jan 25Oxurion NV, Annual General Meeting, May 07, 2024Oxurion NV, Annual General Meeting, May 07, 2024, at 14:00 Central European Standard Time.
お知らせ • Dec 30+ 2 more updatesOxurion Announces CEO ChangesOxurion NV announced it has avoided bankruptcy by entering into a binding letter of intent (LOI) with Atlas Special Opportunities LLC (Atlas) and an addendum to the existing subscription agreement for convertible bonds with Atlas. The Company appointed Pascal Ghoson as the new acting CEO/CFO, who is a former M&A specialist at Rothschild bank and CFO of various listed companies on Euronext. Tom Graney have stepped down from the Board as a condition of the LOI.
お知らせ • Nov 20Oxurion NV Discloses Topline Data from Kalahari Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular EdemaOxurion NV announced that topline data in its KALAHARI Phase 2, Part B clinical trial for Diabetic macular edema (DME) (KALAHARI trial) did not demonstrate that its novel PKal Inhibitor, THR-149, improved vision as much as the comparator, the anti-VEGF therapy aflibercept, at Month 3 (the primary endpoint). The mean change in best corrected visual acuity (BCVA) from baseline at Month 3 was -0.2 letters for theTHR-149 arm and +3.5 letters for the aflibercept arm. The results confirmed that THR-149 was safe and well tolerated. The KALAHARI trial is the only ongoing trial sponsored by Oxurion. In light of these results and the Company's low cash position, the Company has therefore decided to take the necessary steps to file for bankruptcy. Oxurion's investigators over-enrolled the trial with a total of 112 patients, for whom the current standard of care is suboptimal in treating their DME, reflecting the strong interest of both investigators and patients. The KALAHari trial evaluated Oxurion's novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for DME patients who respond suboptimally to anti-VEGF therapy. The continuation of the trial followed the recommendation from an Independent Data Monitoring Committee (IDMC) in December 2022 that it would not be futile for the KALAHARI trial to continue based on the outcome of a pre-specified futility analysis that included an evaluation of interim efficacy and safety data from 31 patients at Month 3 and followed encouraging data from the Part A dose- selection part of the KALAHARI trial.
Board Change • Nov 06High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Independent Non-Executive Director Thomas Clay is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 05First half 2023 earnings released: €0.02 loss per share (vs €0.32 loss in 1H 2022)First half 2023 results: €0.02 loss per share (improved from €0.32 loss in 1H 2022). Net loss: €10.6m (loss narrowed 27% from 1H 2022).
Board Change • Sep 20High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Independent Non-Executive Director Thomas Clay is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 24Oxurion NV to Report First Half, 2023 Results on Sep 29, 2023Oxurion NV announced that they will report first half, 2023 results on Sep 29, 2023
お知らせ • May 26Oxurion NV Reaches Enrollment Target in Kalahari Phase 2, Part B Trial of Novel Pkal Inhibitor Thr-149 in Diabetic Macular EdemaOxurion NV announced that it has reached its enrollment target of 108 patients randomized in its KALAHARI Phase 2, Part B clinical trial for diabetic macular edema (DME) (KALAHARI trial). As of Oxurion’s investigators have successfully enrolled the 108 patients planned for this trial. Given the high level of interest from both investigators and patients, additional patients are still likely to be included in the trial, which would mean the trial will be over-enrolled. As it has now reached its enrollment target, Oxurion confirms its previous guidance that it anticipates reporting top-line data from the KALAHARI trial in the fourth quarter of 2023. The KALAHARI trial is evaluating Oxurion’s novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for DME patients who respond suboptimally to anti-VEGF therapy, the current standard of care. This milestone follows the recommendation from an Independent Data Monitoring Committee (IDMC) in December 2022 that the KALAHARI trial should continue based on the outcome of a pre-specified futility analysis that included an evaluation of interim efficacy and safety data from 31 patients at the three-month time point. Approximately 22 million people worldwide have DME currently, with prevalence increasing due to the growing global diabetic epidemic. DME is the leading cause of vision loss in working-age people, and the market for treatments is currently estimated at +$5 billion. People who suffer from DME have leaking vessels in the back of the eye, leading to a thickening of the retina that causes vision problems such as blurriness in the center of vision, the appearance of dark spots or patches in the field of vision, and colors to look dull. These symptoms may affect the ability to read, write, drive, and recognize faces – presenting a significant patient and caregiver burden.
Board Change • May 19High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Independent Non-Executive Director Thomas Clay is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 21Oxurion NV, Annual General Meeting, May 02, 2023Oxurion NV, Annual General Meeting, May 02, 2023.
Reported Earnings • Feb 24Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: €0.77 loss per share (down from €0.73 loss in FY 2020). Net loss: €29.2m (loss widened 4.1% from FY 2020). Products in clinical trials Phase I: 1 Phase II: 1 Revenue exceeded analyst estimates by 147%. Over the next year, revenue is expected to shrink by 100% compared to a 59% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 20Full year 2020 earnings released: €0.75 loss per share (vs €1.35 loss in FY 2019)Full year 2020 results: Net loss: €28.0m (loss narrowed 46% from FY 2019). Products in clinical trials Phase I: 1 Phase II: 1 Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Nov 28New 90-day high: €2.92The company is up 19% from its price of €2.45 on 28 August 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 5.0% over the same period.
Is New 90 Day High Low • Oct 30New 90-day low: €2.35The company is down 15% from its price of €2.78 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 14% over the same period.
Is New 90 Day High Low • Oct 01New 90-day low: €2.40The company is down 20% from its price of €3.02 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.
Reported Earnings • Sep 19First half earnings releasedOver the last 12 months the company has reported total losses of €31.6m, with losses narrowing by 44% from the prior year.
